Developmentally Informed Pharmacotherapy for Child and Adolescent Depressive Disorders

被引：13
|
作者：
Sakolsky, Dara [1 ]
Birmaher, Boris [1 ]
机构：
[1] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA
来源：
CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA | 2012年 / 21卷 / 02期
关键词：
Major depressive disorder; Adolescents; Children; Selective serotonin reuptake inhibitors; Venlafaxine; PLACEBO-CONTROLLED TRIAL; SEROTONIN REUPTAKE INHIBITORS; COGNITIVE-BEHAVIORAL THERAPY; DOUBLE-BLIND; MAJOR DEPRESSION; ANTIDEPRESSANT TREATMENT; RESISTANT DEPRESSION; FOLLOW-UP; FLUOXETINE; SUICIDE;
D O I：
10.1016/j.chc.2012.01.005
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
This article reviews evidence-based pharmacotherapy for children and adolescents with depression. Several randomized controlled trials (RCTs) support the use of fluoxetine for the treatment of childhood and adolescent depression as well as escitalopram in the treatment of adolescent depression. To date, one RCT has demonstrated the effectiveness of sertraline or citalopram for the treatment of major depressive disorder in youth. Only a small number of RCTs for depression have included children, and none of these trials were adequately powered to detect differences in the efficacy of medication between children and adolescents.
引用
收藏
页码：313 / +
页数：14
相关论文
共 50 条
12345